LM Diagnostic Assay

by | May 15, 2024 | LM

“Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern...

LM Acquistition Meeting

by | May 9, 2024 | LM

Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning’s investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...

ReSPECT-LM at North Shore

by | May 2, 2024 | LM

❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of North Shore University Hospital in New York to our ReSPECT-LM Clinical Trial with Principal Investigator Michael Schulder, M.D.. This site is NOW ENROLLING patients. Michael Schulder,...

LBBC Metastatic BC Conference

by | Apr 24, 2024 | LM

Thank you to everyone who came by our booth at #LBBCMetsConf this last weekend! If you missed us or would like to learn more about our Leptomeningeal Metastases clinical trial for Metastatic Breast Cancer patients, you can visit our website at...

“Thriving Together”

by | Apr 19, 2024 | LM

Come by our NEW booth at the Living Beyond Breast Cancer Metastatic Breast Cancer Conference this weekend! We have information about Leptomeningeal Metastases and our ongoing ReSPECT-LM Clinical Trial. See you there! 🎗️ ReSPECT-LM Website:...

LBBC Curtain Raiser

by | Apr 11, 2024 | LM

📣 Mark Your Calendars! Plus Therapeutics will be exhibiting at the @livingbeyondbc Thriving Together Metastatic Breast Cancer Conference, April 19-21. Come learn about our ReSPECT-LM clinical trial for Leptomeningeal Metastases and meet some of our team. Event...